dna-11k_2007.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

________________________

FORM 11-K

________________________

(Mark One)
  
þ
ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2007
 
OR

o
TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                to               .

Commission File Number: 1-9813

A.
Full title of the plan and the address of the plan if different from that of the issuer named below:
   
GENENTECH, INC. TAX REDUCTION INVESTMENT PLAN
   
B.
Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:
   
GENENTECH, INC.
1 DNA Way
South San Francisco, California  94080-4990



 
 
 


Genentech, Inc. Tax Reduction Investment Plan

Index to Financial Statements


Item
Page No.
   
Report of Independent Registered Public Accounting Firm
2
   
Statements of Net Assets Available for Benefits at December 31, 2007 and 2006
3
   
Statements of Changes in Net Assets Available for Benefits for the Years Ended December 31, 2007 and 2006
4
   
Notes to Financial Statements
5-9
   
Supplemental Schedule:
Schedule H, Line 4i — Schedule of Assets (Held At End of Year)
 
10
   
Signatures
11
   
Exhibit
12

In this report, “Genentech,” “we,” “us”, “our” and “the Company” refer to Genentech, Inc. “Common Stock” refers to Genentech’s Common Stock, par value $0.02 per share.

 
-1-
 


Report of Independent Registered Public Accounting Firm


To the Participants and Plan Administrative Committee of the
Genentech, Inc. Tax Reduction Investment Plan

We have audited the accompanying statements of net assets available for benefits of the Genentech, Inc. Tax Reduction Investment Plan as of December 31, 2007 and 2006, and the related statements of changes in net assets available for benefits for the years then ended. These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Plan’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2007 and 2006, and the changes in its net assets available for benefits for the years then ended, in conformity with U.S. generally accepted accounting principles.

Our audits were performed for the purpose of forming an opinion on the financial statements taken as a whole. The accompanying supplemental schedule of assets (held at end of year) as of December 31, 2007, is presented for purposes of additional analysis and is not a required part of the financial statements but is supplementary information required by the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. This supplemental schedule is the responsibility of the Plan’s management. The supplemental schedule has been subjected to the auditing procedures applied in our audits of the financial statements and, in our opinion, is fairly stated in all material respects in relation to the financial statements taken as a whole.

 
/s/ Ernst & Young LLP


San Jose, California
June 9, 2008

 
-2-
 


Genentech, Inc. Tax Reduction Investment Plan

Statements of Net Assets Available for Benefits


   
December 31,
  
   
2007
    
2006
  
Assets
            
Investments, at fair value
   $ 1,147,862,195     $ 916,508,076  
Cash
     387,416       251,658  
Receivables
                
Employer contributions
     30,391,223       24,911,078  
Investment income
     3,336       3,773  
Total receivables
     30,394,559       24,914,851  
                 
Net assets available for benefits at fair value
     1,178,644,170       941,674,585  
Adjustment from fair value to contract value (for interest in common collective trust related to fully benefit-responsive investment contracts)
     723,549       910,831  
Net assets available for benefits
   $ 1,179,367,719     $ 942,585,416  

See accompanying notes.

 
-3-
 


Genentech, Inc. Tax Reduction Investment Plan

Statements of Changes in Net Assets Available for Benefits


   
Year Ended December 31,
  
   
2007
    
2006
  
ADDITIONS
            
Investment income
            
Interest and dividends
   $ 79,367,051     $ 49,242,066  
Realized and unrealized gain, net
     1,459,197       14,444,208  
Total investment income
     80,826,248       63,686,274  
                 
Contributions
                
Employee
     101,632,349       85,936,883  
Employee rollover
     14,781,609       19,398,630  
Employer
     79,851,304       67,725,351  
Total contributions
     196,265,262       173,060,864  
Total additions
     277,091,510       236,747,138  
                 
DEDUCTIONS
                
Benefit payments
     51,564,975       32,665,973  
Administrative expenses
     95,490       41,333  
Total deductions
     51,660,465       32,707,306  
                 
Transfer in
     11,351,258       –  
Net increase
     236,782,303       204,039,832  
Net assets available for benefits
                
Beginning of year
     942,585,416       738,545,584  
End of year
   $ 1,179,367,719     $ 942,585,416  

See accompanying notes.

 
-4-
 


Genentech, Inc. Tax Reduction Investment Plan

Notes to Financial Statements

December 31, 2007


(1)
PLAN DESCRIPTION

The following description of the Genentech, Inc. Tax Reduction Investment Plan (Plan) provides only general information. Participants should refer to the plan document for a more complete description of the Plan’s provisions.

General
The Plan is a defined contribution plan, effective January 1, 1985 and amended and restated as of November 1, 2007, established by Genentech (Plan Sponsor and Plan Administrator) for the benefit of eligible employees of the Company and its participating affiliates. It is subject to the provisions of the Employee Retirement Investment Security Act of 1974, as amended (ERISA).

Individuals eligible to participate under the Plan must be employees of Genentech or employees of an affiliate of Genentech that adopts the Plan with the approval of the Board of Directors of the Plan Sponsor. Such employees become eligible immediately upon hire. However, the following employees or classes of employees are not eligible to participate: (1) any employee who is a member of a collective bargaining unit and who is covered by a collective bargaining agreement where retirement benefits were the subject of good faith bargaining, unless the agreement specifically provides coverage of such employee under the Plan; (2) any individual employed by any corporation or other business entity that is merged or liquidated into Genentech, unless the Administrative Committee for the Plan (Committee) designates such employees as eligible employees; (3) any employee paid from a non-United States (U.S.) payroll; (4) an employee who does not have a U.S. social security number; or (5) any employee classified or treated as an independent contractor, consultant, leased employee (as defined under the Internal Revenue Code of 1986, as amended (Code)), or an employee of an employment agency or other entity, even if subsequently determined to have been a common-law employee of Genentech.

In August 2007, the Company acquired Tanox, Inc. (Tanox). Former Tanox employees who joined Genentech were eligible to participate in the Plan, and the account balances of these new employees under the former Tanox, Inc. 401(k) Plan, totaling $11,351,258, were transferred to the Plan in November 2007.

Contributions
Each year, participants may contribute up to 50 percent of annual pre-tax compensation, as defined in the Plan. Participants aged 50 years and older may include a catch-up contribution for a total contribution of up to 75 percent of annual pre-tax compensation. Each participant may also contribute up to 99 percent of his or her eligible bonus, as defined in the Plan. Subject to limitations of the Code, each participant in the Plan could elect to defer up to the lesser of $15,500 or 50 percent of his or her eligible compensation in 2007 and $15,000 or 50 percent of his or her eligible compensation in 2006. Each participant aged 50 years and older in the Plan who made a catch-up contribution could elect to defer up to the lesser of $20,500 or 75 percent of his or her eligible compensation in 2007 and $20,000 or 75 percent of his or her eligible compensation in 2006.

Contributions are made through participant systematic salary reductions. The participant’s salary is reduced by the elected savings amount (salary deferral contributions) on a pre-tax basis. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans.

The Company contributes 100 percent of the first 5 percent of eligible compensation that the participant contributes to the Plan (Match). Effective October 1, 2006 the Match is funded concurrently with a participant’s semi-monthly contribution to the Plan. In October 2006, the Company funded a one-time matching contribution for the period from January 1, 2006 through September 29, 2006.

 
-5-
 

In 2007 and 2006, the Company also provided a nonelective contribution equal to two percent of eligible compensation of eligible participants employed on the last business day of the year (Nonelective Contribution).The Nonelective Contribution was funded in the first quarter of the subsequent year. The Nonelective Contribution was $24,825,957 and $20,835,002 in 2007 and 2006, respectively.

Participants direct the investments of their contributions into various investment options offered by the Plan. The Plan currently offers investments in mutual funds, a common collective trust, the Company’s Common Stock, and certain other individual securities and a money market fund available through a brokerage account. Effective September 30, 2006, investments in Genentech Common Stock are limited to 30 percent of a participant’s future contributions.

All amounts contributed to the Plan are deposited in a trust account with Fidelity Management Trust Company (Plan Trustee). The Plan Trustee has blanket bond insurance covering the full market value of the securities and investments in its custody.

Participant Accounts
Each participant’s account is credited with the participant’s contribution, the Match, the Nonelective Contribution and Plan earnings. An individual participant’s account is credited with Plan earnings or losses on a pro rata basis as the actual investment funds report their earnings performance. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.

Vesting
Participants are 100 percent vested immediately in all contributions to the Plan plus actual earnings thereon.

Participant Loans
Participants may borrow from their fund accounts a minimum of $1,000 up to a maximum equal to the lesser of (1) $50,000, less the highest outstanding loan balance during the preceding twelve months, or (2) 50 percent of their vested account balance. The loans are secured by the balance in the participant’s account and bear fixed interest rates (presently two percent above the bank prime interest rate). Principal and interest are paid ratably through monthly payroll deductions over three or five years, or fifteen years if the purpose of the loan is to purchase a participant’s principal residence. Trustee fees related to the establishment and administration of the loans are deducted from each of the applicable participant’s accounts.

Administrative Expenses
Certain administrative fees, such as accounting, legal, and consulting fees are paid by the Plan Sponsor.

Payment of Benefits
On termination of service due to a participant’s death, disability, retirement, attainment of age 70-1/2 (applicable only to participants who own 5 percent or more of Genentech’s Common Stock), or termination of service for other reasons, or authorized exercise of a participant’s withdrawal rights under the Plan, a participant may receive a lump-sum amount equal to the value of the participant’s vested interest in his or her account. Upon termination, a participant must consent to a distribution if his or her account balance under the Plan exceeds $1,000. Distributions are made upon receipt of the participant’s or beneficiary’s election directing the method of distribution.

Anytime prior to termination of employment with the Company, the Committee may grant a participant’s request for a withdrawal from the participant’s account if the Committee makes a determination that such withdrawal is necessary in light of the immediate and significant financial needs of the participant and is in accordance with the requirements of the Code and regulations promulgated there under. In addition, a Plan participant may withdraw up to the entire balance of his or her Plan account if over age 59-1/2.

 
-6-
 



(2)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Accounting
The accompanying financial statements of the Plan are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (GAAP) and are presented in accordance with the financial reporting requirements of ERISA.

Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosures of contingent assets and liabilities. Actual results could differ from those estimates.

Recent Accounting Pronouncements
In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (FAS 157). FAS 157 establishes a framework for measuring fair value in GAAP and clarifies the definition of fair value within that framework. FAS 157 does not require assets and liabilities that were previously recorded at cost to be recorded at fair value. FAS 157 is effective for fiscal years beginning after November 15, 2007, and is effective for the Plan beginning January 1, 2008. We do not expect the adoption of FAS 157 to have a material effect on the Plan.

Investment Valuation and Income Recognition
The Plan investments are stated at quoted market prices on the last business day of the year to value mutual funds. Shares of mutual funds are valued at the net asset values of shares held by the Plan at year-end. Participant loans are valued at their outstanding balance, which approximates fair value. Common stock is valued at the quoted market price on the last day of the plan year. All purchase and sales of securities are recorded on a trade-date basis. Gains and losses on the disposal of investments are determined based on the average cost of all securities. Dividend income is recorded based on the ex-dividend date. Income from other investments is recorded as earned on an accrual basis.

As described in Financial Accounting Standards Board Staff Position (FSP) AAG INV-1 and SOP 94-4-1, “Reporting of Fully Benefit-Responsive Investment Contracts Held by Certain Investment Companies Subject to the AICPA Investment Company Guide and Defined-Contribution Health and Welfare and Pension Plans” (the FSP), investment contracts held by a defined contribution plan are required to be reported at fair value. However, contract value is the relevant measurement attribute for that portion of the net assets available for benefits of a defined contribution plan attributable to fully benefit-responsive investment contracts because contract value is the amount participants would receive if they were to initiate permitted transactions under the terms of the Plan. The Plan invests in investment contracts through a common collective trust (Fidelity Managed Income Portfolio II (MIP Fund)). As required by the FSP, the statements of net assets available for benefits present the fair value of the MIP Fund and the adjustment from fair value to contract value. The fair value of the Plan’s interest in the MIP Fund is based on information reported by the issuer of the common collective trust at year-end. The contract value of the MIP Fund represents contributions plus earnings, less participant withdrawals and administrative expenses.

In accordance with the FSP, the Plan reflected the MIP fund at fair value and recognized an adjustment from fair value to contract value for the fully benefit-responsive investment contract of $723,549 and $910,831 as of December 31, 2007 and 2006, respectively, in the accompanying Statements of Net Assets Available for Benefits.

Payment of Benefits
Benefits are recorded when paid.

 
-7-
 


Risks and Uncertainties
The Plan provides for various investment options in common stock, mutual funds and common collective trust funds. Investment securities, in general, are exposed to various risks, such as interest rate, credit and overall market volatility risk. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and those changes could materially affect the amounts reported in the Statements of Net Assets Available for Benefits.


(3)
INVESTMENTS

The following presents the fair value of investments that represent five percent or more of the Plan’s net assets.

   
December 31,
  
   
2007
    
2006
  
Fidelity Growth Company Fund
   $ 132,701,716     $ 99,927,141  
Fidelity Diversified International Fund
     123,171,342       81,052,622  
Neuberger & Berman Genesis Institutional Fund
     114,684,397       81,122,241  
Spartan 500 Index Advantage
     114,270,245       –  
Fidelity Balanced Fund
     99,173,484       79,047,698  
Fidelity Managed Income Portfolio II
     95,434,286       75,965,317  
Genentech Common Stock
     73,818,136       96,072,809  
Fidelity Magellan Fund
     60,953,468       57,233,624  
PIMCO Total Return Fund
     59,864,775       *  
Fidelity U.S. Equity Index Pool
     *       100,506,389  
___________
*
Amount represents less than 5% of net assets at year end.

During 2007 and 2006, the Plan’s investments (including gains and losses on investments bought and sold, as well as held during the year) appreciated in fair value by $1,459,197 and $14,444,208, respectively.

   
Net Realized and Unrealized Appreciation (Depreciation) in Fair Value of Investments
  
   
2007
    
2006
  
Common stock
   $ (15,577,727 )   $ (11,832,513 )
Mutual funds
     11,382,729       13,165,402  
Common collective trust
     5,654,195       13,111,319  
    $ 1,459,197     $ 14,444,208  


(4)
PARTY-IN-INTEREST TRANSACTIONS

Certain Plan investments are shares of mutual funds managed by the Plan Trustee and, therefore, these transactions qualify as party-in-interest transactions. Certain investment management fees, such as recordkeeping fees and trust/custody fees, paid to the Plan Trustee are deducted from investment returns and reduce the net asset values of the investments. Fees paid by plan participants for loan setup and loan maintenance, short term trading and overnight billing services amounted to $95,490 and $41,333 for the years ended December 31, 2007 and 2006, respectively. The fees for the year ended December 31, 2007 also included fees paid by the Plan for investment advisory services.

Transactions in shares of Genentech Common Stock qualify as party-in-interest transactions under the provisions of ERISA. During 2007 and 2006, the Plan made purchases of $7,275,082 and $22,183,035, respectively, and sales of $12,312,762 and $6,935,965, respectively, of Genentech Common Stock on behalf of its participants. In addition, the Plan made in-kind transfers of Genentech Common Stock to participants of $1,435,723 during 2007 and $900,565 during 2006.

 
-8-
 


(5)
PLAN TERMINATION

Although it has not expressed any intent to do so, the Company’s Board of Directors has the right under the Plan to discontinue its contributions at any time and to alter, amend or terminate the Plan, or any part of the Plan, subject to the provision of ERISA. In the event of Plan termination, participants would remain 100 percent vested in their employer contributions. The balances credited to their accounts would remain with the Plan Trustee until the balances become distributable in accordance with the Plan.


(6)
TAX STATUS

The Plan received a determination letter from the Internal Revenue Service dated March 18, 2003, stating that the Plan is qualified under Section 401(a) of the Code and, therefore, the related trust is exempt from taxation. Subsequent to this determination by the Internal Revenue Services, the Plan was amended and restated. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualification. The Plan administrator believes the Plan is being operated in compliance with the applicable requirements of the Code and, therefore, believes that the Plan, as amended and restated, is qualified and the related trust is tax exempt.


(7)
RECONCILIATION OF FINANCIAL STATEMENTS TO FORM 5500

The following is a reconciliation of the Statements of Net Assets Available for Benefits per the financial statements at December 31, 2007 and 2006 to the Form 5500:

Statement of Net Assets Available for Benefits
  
2007
    
2006
  
Net assets available for benefits per the financial statements
   $ 1,179,367,719     $ 942,585,416  
Adjustment from contract value to fair value (for interest in a collective common collective trust related to fully benefit-responsive investment contracts)
     (723,549 )     (910,831 )
Net assets available for benefits per the Form 5500
   $ 1,178,644,170     $ 941,674,585  

The following is a reconciliation of the Statements of Changes in Net Assets Available for Benefits per the financial statements for the years ended December 31, 2007 and 2006 to the Form 5500:

   
2007
    
2006
  
Total investment income per the financial statements
   $ 80,826,248     $ 63,686,274  
Less: Current year adjustment from contract value to fair value (for interest in a collective common collective trust related to fully benefit-responsive investment contracts)
     (723,549 )     (910,831 )
Add: Prior year adjustment from contract value to fair value (for interest in a collective common collective trust related to fully benefit-responsive investment contracts)
     910,831       –  
Total income per the Form 5500
   $ 81,013,530     $ 62,775,443  

 
-9-
 


Genentech, Inc. Tax Reduction Investment Plan

EIN: 94-2347624, Plan #001

Schedule H, Line 4i — Schedule of Assets (Held At End of Year)

December 31, 2007

(a)
  
(b)
  
(c)
  
(e)
  
   
Identity of issuer, borrower, lessor or similar party
  
Description of investment including maturity date, rate of interest, collateral, par, or maturity value(1)
  
Current Value
  
   
Mutual Funds:
              
 
*
  
Fidelity Magellan Fund
     649,339  
 shares
   $ 60,953,468  
 
*
  
Fidelity Growth Company Fund
     1,599,201  
 shares
     132,701,716  
 
*
  
Fidelity Balanced Fund
     5,057,291  
 shares
     99,173,484  
 
*
  
Fidelity Diversified International Fund
     3,087,001  
 shares
     123,171,342  
 
*
  
Fidelity Freedom Income Fund
     253,291  
 shares
     2,900,183  
 
*
  
Fidelity Freedom 2000 Fund
     73,000  
 shares
     903,011  
 
*
  
Fidelity Freedom 2010 Fund
     605,952  
 shares
     8,980,212  
 
*
  
Fidelity Freedom 2020 Fund
     1,639,965  
 shares
     25,927,839  
 
*
  
Fidelity Freedom 2030 Fund
     1,551,704  
 shares
     25,634,142  
 
*
  
Fidelity Freedom 2040 Fund
     2,032,738  
 shares
     19,778,538  
 
*
  
Fidelity Small Cap Stock Fund
     2,020,654  
 shares
     35,219,999  
     
PIMCO Total Return Fund
     5,600,072  
 shares
     59,864,775  
     
Clipper Fund
     641,613  
 shares
     51,970,679  
     
Neuberger & Berman Genesis Institutional Fund
     2,431,299  
 shares
     114,684,397  
     
Domini Social Equity Fund
     674,438  
 shares
     7,351,379  
     
GMO U.S. Core Equity Fund
     1,757,847  
 shares
     23,326,624  
     
Laudus Rosenberg International Small Capitalization Fund
     2,343,142  
 shares
     41,637,629  
     
Spartan 500 Index Advantage
     1,127,815  
 shares
     114,270,245  
                         
     
Common Collective Trusts:
                  
 
*
  
Fidelity Managed Income Portfolio II
     96,157,835  
 units
     95,434,286  
                         
     
Money Market Funds:
                  
 
*
  
Fidelity Institutional Cash Portfolio
     649,456  
 shares
     649,456  
                         
 
*
  
Genentech Common Stock
     1,101,417  
 shares
     73,818,136  
                         
 
*
  
Assets in Brokerage Link Accounts(4)
       (2)            17,267,098  
                         
 
*
  
Participant Loans
       (3)            12,243,557  
                         
     
Total Investments
             $ 1,147,862,195  
___________
(1)
Cost information is not provided as all investments are participant directed.
(2)
Various investments, including common stocks, mutual funds and money market funds.
(3)
Maturing at various dates through 2022 at interest rates ranging from 6.0% to 11.5%.
(4)
Certain investments in the Brokerage Link Accounts are issued by a party-in-interest to the Plan.
   
*
Indicates party-in-interest to the Plan.

 
-10-
 


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Plan Administrator has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.


Genentech, Inc. Tax Reduction Investment Plan
by Genentech, Inc., Plan Administrator


Date:
  June 23, 2008
  
/s/ DAVID A. EBERSMAN
     
David A. Ebersman
Executive Vice President and
Chief Financial Officer
and Plan Administrative Committee
Member for Genentech, Inc.
Tax Reduction Investment Plan
       
       
Date:
  June 23, 2008
  
/s/ ROBERT E. ANDREATTA
     
Robert E. Andreatta
Controller and Chief Accounting Officer
and Plan Administrative Committee
Member for Genentech, Inc.
Tax Reduction Investment Plan

 
-11-
 


Genentech, Inc. Tax Reduction Investment Plan

Index of Exhibit Filed with Form 11-K
For the Year Ended December 31, 2007

Exhibit Number
Description
23.1
Consent of Independent Registered Public Accounting Firm, filed with this document


 
-12-